Meeting
2022 ASCO Annual Meeting
Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
Authors
Anne S. Tsao
The University of Texas MD Anderson Cancer Center, Houston, TX
Anne S. Tsao , Zihe Song , Alan Loh Ho , Janice M. Mehnert , Edith P. Mitchell , John Joseph Wright , Naoko Takebe , Robert James Gray , Victoria Wang , Lisa McShane , Larry V. Rubinstein , David R. Patton , P. Mickey Williams , Stanley R. Hamilton , Barbara A. Conley , Carlos L. Arteaga , Lyndsay Harris , Peter J. O'Dwyer , Alice P. Chen , Keith Flaherty
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT02465060
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3010)
DOI
10.1200/JCO.2022.40.16_suppl.3010
Abstract #
3010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).
First Author: Amar J. Gajjar
Poster
2016 ASCO Annual Meeting
MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway.
First Author: Didier Frappaz
Poster
2014 Gastrointestinal Cancers Symposium
A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).
First Author: Ana De Jesus-Acosta
Poster
2013 ASCO Annual Meeting
Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.
First Author: Daniel Virgil Thomas Catenacci